Journal
DRUG AND ALCOHOL DEPENDENCE
Volume 160, Issue -, Pages 82-89Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.drugalcdep.2015.12.035
Keywords
Opioid use disorder; Opioid agonist treatment; Buprenorphine; Methadone; Demographics
Categories
Funding
- VA/OAA Interprofessional Advanced Fellowship in Addiction Treatment
- Research in Addiction Medicine Scholars (RAMS) Program from the National Institute on Drug Abuse [R25DA033211]
- VA New England Mental Illness, Research, Education and Clinical Center
Ask authors/readers for more resources
Background: The advent of buprenorphine as an alternative to methadone has dramatically shifted the landscape of opioid agonist therapy (OAT) for opioid use disorder (OUD). However, there is limited US national level data describing thedifferences between patients who are prescribed these two OAT options. Methods: From veterans with OUD diagnosis who used Veterans Health Administration services in 2012, we identified 3 mutually exclusive groups: those who received (1) buprenorphine only (n =5,670); (2) methadone only (n=6,252); or (3) both buprenorphine and methadone in the same year (n = 2513). We calculated the bi-varate effect size differences (risk ratios and Cohen's d) forcharacteristics that differentiated these groups. Logistic regression analysis was then used to identify factors independently differentiating the groups. Results: Ten year increment in age (OR 0.67; 95% CI 0.64-0.70), urban residence (OR 0.26; 95% CI 0.25-0.33), and black race (OR 0.39; 95% CI 0.35-0.43) were strongly and negatively associated with odds of receiving buprenorphine compared to methadone, while medical and psychiatric comorbidities or receipt of other psychiatric medications did not demonstrate substantial differences between groups. Conclusions: Differences between veterans receiving buprenorphine or methadone based OAT seems to be largely shaped by demographic characteristics rather than medical or psychiatric or service use characteristics. A clearer understanding of the reasons for racial differences could be helpful in assuring that black OUD patients are not denied the opportunity to receive buprenorphine if that is their preference. Published by Elsevier Ireland Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available